2022 Liquid Biopsy Surveillance & Early Detection Summit: November 17


Erin Newburn, MS PhD
November 17, 2022 | 1:00 PM ET

NeXT Personal: NextGen MRD Testing for Solid Tumors

The ability to monitor and predict molecular recurrence at the earliest timepoints during or after curative therapy in patients previously diagnosed with cancer may inform precision treatment regimens, or spare patients from costly side effects. Here we discuss NeXT Personal, an advanced next generation MRD platform optimized for sensitivity.